

## QSX-Enh-P HER2, ASR (Clone CB11)

Catalog Number:	AP31063-004
Format/ Size:	Cartridge, 4mL
Dilution:	Ready-to-use

### Intended Use:

Analyte Specific Reagent. Analytical and performance characteristics are not established.

### Summary and Explanation:

QSX-Enh HER2, clone (CB11) is a ligand-less member of the epidermal growth factor receptor family of tyrosine kinases. HER2 functions as a co-receptor for a variety of epidermal growth factor ligands that bind to activate HER2. This ready-to-use mouse monoclonal antibody against human HER2. The antibody has been pre-diluted and optimized for IHC use without further dilution.

Clone	Species	Total Protein Conc.
CB11	Mouse	10 mg/ml

### Application:

Immunohistochemistry.

### Supplied As:

Liquid, buffered protein reagent with ProClin™ 300 preservative.

### Storage and Handling:

This product should be stored at 2-8°C and is suitable for use until expiration date when stored at this temperature. Do not freeze. Do not use the product after expiration date unless dating extension information is provided by Novodix.

### Specimen Preparation:

#### Paraffin Sections:

Tissues routinely processed, neutral buffered 10% formalin-fixed are suitable for use prior to paraffin embedding. Consult references (Kiernan, 1981; Sheehan & Hrapchak, 1980). Variable results may occur as a result of prolonged fixation. Each section should be cut to the appropriate thickness (approximately 4-5 µm) and placed on a positively charged glass slide. Slides containing the tissue section may be baked for at least one hour but not exceeding 24 hours in a 58-60°C±5°C oven. Osseous tissues should be decalcified prior to tissue processing to facilitate tissue cutting and prevent damage to microtome blades (Kiernan, 1981; Sheehan & Hrapchak, 1980).

### Bibliography:

1. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
2. Sheehan DC and Hrapchak BB. Theory and Practice of Histotechnology. St. Louis: C.V. Mosby Co. 1980.
3. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med, 1983;14:767-771.
4. Alred D.C. Mod Pathol. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer, 2010;23:S52-9.
5. Bauer K. et al. BMC Cancer, Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer, 2010 May 21;10:228
6. Harvey J.M. J Clin Oncol. 1999; 17:1474-81.

